Gilead Free Cash Flow vs Enterprise Value Analysis

GILD Stock

USD 66.93 0.38 0.56%

Gilead Sciences financial indicator trend analysis is much more than just examining Gilead Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gilead Sciences is a good investment. Please check the relationship between Gilead Sciences Free Cash Flow and its Enterprise Value accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Free Cash Flow vs Enterprise Value

Free Cash Flow vs Enterprise Value Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gilead Sciences Free Cash Flow account and Enterprise Value. At this time, the significance of the direction appears to have strong relationship.

The correlation between Gilead Sciences' Free Cash Flow and Enterprise Value is 0.62. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Enterprise Value in the same time period over historical financial statements of Gilead Sciences, assuming nothing else is changed. The correlation between historical values of Gilead Sciences' Free Cash Flow and Enterprise Value is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Gilead Sciences are associated (or correlated) with its Enterprise Value. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Enterprise Value has no effect on the direction of Free Cash Flow i.e., Gilead Sciences' Free Cash Flow and Enterprise Value go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as Gilead Sciences theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Gilead Sciences debt, but would also pocket its cash. Enterprise Value is more accurate representation of Gilead Sciences value than its market capitalization because it takes into account all of Gilead Sciences existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.31, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.

	2021	2022	2023	2024 (projected)
Total Revenue	27.3B	27.3B	27.1B	28.5B
Interest Expense	1.0B	935M	944M	534.5M

Total Revenue Interest Expense

Gilead Sciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab	Other Assets
Total Assets		0.85	0.9	0.98	0.95	0.91	0.7	0.93	-0.05	0.4	0.83	0.26	0.52	0.18	0.98	-0.12	-0.27	0.99	0.61	0.62	0.73	0.8	0.47	0.54	0.56	0.53
Short Long Term Debt Total	0.85		0.72	0.78	0.71	0.82	0.94	0.68	-0.2	0.18	0.75	0.35	0.41	-0.07	0.89	0.07	-0.23	0.88	0.45	0.68	0.37	0.72	0.53	0.38	0.53	0.49
Other Current Liab	0.9	0.72		0.93	0.9	0.81	0.64	0.87	-0.1	0.2	0.75	0.12	0.45	0.19	0.85	-0.2	-0.53	0.88	0.53	0.42	0.65	0.78	0.36	0.57	0.47	0.32
Total Current Liabilities	0.98	0.78	0.93		0.96	0.9	0.66	0.91	0.0	0.32	0.85	0.25	0.44	0.25	0.93	-0.19	-0.31	0.96	0.54	0.59	0.73	0.82	0.39	0.62	0.55	0.45
Total Stockholder Equity	0.95	0.71	0.9	0.96		0.88	0.54	0.95	0.03	0.44	0.78	0.22	0.49	0.34	0.87	-0.18	-0.36	0.9	0.59	0.52	0.74	0.79	0.41	0.6	0.46	0.37
Property Plant And Equipment Net	0.91	0.82	0.81	0.9	0.88		0.75	0.77	-0.25	0.18	0.95	0.47	0.17	0.05	0.87	-0.07	-0.4	0.89	0.26	0.68	0.57	0.96	0.23	0.73	0.62	0.35
Net Debt	0.7	0.94	0.64	0.66	0.54	0.75		0.48	-0.27	-0.17	0.75	0.37	0.15	-0.18	0.76	-0.01	-0.24	0.75	0.19	0.62	0.21	0.71	0.35	0.44	0.54	0.41
Retained Earnings	0.93	0.68	0.87	0.91	0.95	0.77	0.48		-0.03	0.55	0.64	0.07	0.68	0.19	0.88	-0.27	-0.28	0.9	0.76	0.44	0.77	0.65	0.54	0.37	0.4	0.47
Accounts Payable	-0.05	-0.2	-0.1	0.0	0.03	-0.25	-0.27	-0.03		0.23	-0.22	-0.44	0.19	0.82	-0.11	0.21	0.47	-0.09	0.23	-0.31	0.27	-0.31	-0.11	0.05	-0.26	0.06
Cash	0.4	0.18	0.2	0.32	0.44	0.18	-0.17	0.55	0.23		-0.02	-0.08	0.74	0.29	0.38	0.21	0.11	0.37	0.76	0.16	0.48	0.02	0.51	-0.19	-0.03	0.28
Non Current Assets Total	0.83	0.75	0.75	0.85	0.78	0.95	0.75	0.64	-0.22	-0.02		0.53	-0.04	0.07	0.81	-0.11	-0.33	0.83	0.08	0.68	0.55	0.93	0.07	0.8	0.71	0.39
Non Currrent Assets Other	0.26	0.35	0.12	0.25	0.22	0.47	0.37	0.07	-0.44	-0.08	0.53		-0.31	-0.09	0.26	0.12	-0.13	0.26	-0.29	0.82	-0.12	0.47	0.21	0.32	0.42	0.03
Cash And Short Term Investments	0.52	0.41	0.45	0.44	0.49	0.17	0.15	0.68	0.19	0.74	-0.04	-0.31		0.14	0.53	-0.04	0.06	0.51	0.99	0.12	0.44	-0.01	0.8	-0.32	-0.05	0.39
Common Stock Shares Outstanding	0.18	-0.07	0.19	0.25	0.34	0.05	-0.18	0.19	0.82	0.29	0.07	-0.09	0.14		0.06	0.2	0.1	0.1	0.2	-0.07	0.35	0.02	-0.06	0.35	-0.09	0.0
Non Current Liabilities Total	0.98	0.89	0.85	0.93	0.87	0.87	0.76	0.88	-0.11	0.38	0.81	0.26	0.53	0.06		-0.06	-0.2	1.0	0.61	0.64	0.69	0.75	0.5	0.45	0.59	0.61
Other Current Assets	-0.12	0.07	-0.2	-0.19	-0.18	-0.07	-0.01	-0.27	0.21	0.21	-0.11	0.12	-0.04	0.2	-0.06		0.08	-0.09	-0.05	-0.03	-0.12	-0.04	-0.08	0.02	0.02	-0.05
Other Stockholder Equity	-0.27	-0.23	-0.53	-0.31	-0.36	-0.4	-0.24	-0.28	0.47	0.11	-0.33	-0.13	0.06	0.1	-0.2	0.08		-0.23	0.05	-0.11	-0.04	-0.52	0.08	-0.45	-0.03	0.35
Total Liab	0.99	0.88	0.88	0.96	0.9	0.89	0.75	0.9	-0.09	0.37	0.83	0.26	0.51	0.1	1.0	-0.09	-0.23		0.6	0.64	0.71	0.77	0.49	0.49	0.58	0.58
Total Current Assets	0.61	0.45	0.53	0.54	0.59	0.26	0.19	0.76	0.23	0.76	0.08	-0.29	0.99	0.2	0.61	-0.05	0.05	0.6		0.15	0.58	0.08	0.75	-0.19	0.02	0.44
Short Term Debt	0.62	0.68	0.42	0.59	0.52	0.68	0.62	0.44	-0.31	0.16	0.68	0.82	0.12	-0.07	0.64	-0.03	-0.11	0.64	0.15		0.17	0.6	0.52	0.31	0.4	0.21
Net Receivables	0.73	0.37	0.65	0.73	0.74	0.57	0.21	0.77	0.27	0.48	0.55	-0.12	0.44	0.35	0.69	-0.12	-0.04	0.71	0.58	0.17		0.47	0.12	0.44	0.33	0.47
Property Plant And Equipment Gross	0.8	0.72	0.78	0.82	0.79	0.96	0.71	0.65	-0.31	0.02	0.93	0.47	-0.01	0.02	0.75	-0.04	-0.52	0.77	0.08	0.6	0.47		0.06	0.79	0.63	0.17
Short Term Investments	0.47	0.53	0.36	0.39	0.41	0.23	0.35	0.54	-0.11	0.51	0.07	0.21	0.8	-0.06	0.5	-0.08	0.08	0.49	0.75	0.52	0.12	0.06		-0.35	0.06	0.32
Inventory	0.54	0.38	0.57	0.62	0.6	0.73	0.44	0.37	0.05	-0.19	0.8	0.32	-0.32	0.35	0.45	0.02	-0.45	0.49	-0.19	0.31	0.44	0.79	-0.35		0.43	0.07
Other Liab	0.56	0.53	0.47	0.55	0.46	0.62	0.54	0.4	-0.26	-0.03	0.71	0.42	-0.05	-0.09	0.59	0.02	-0.03	0.58	0.02	0.4	0.33	0.63	0.06	0.43		0.65
Other Assets	0.53	0.49	0.32	0.45	0.37	0.35	0.41	0.47	0.06	0.28	0.39	0.03	0.39	0.0	0.61	-0.05	0.35	0.58	0.44	0.21	0.47	0.17	0.32	0.07	0.65

Click cells to compare fundamentals

Gilead Sciences Account Relationship Matchups

Gilead Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.6B	68.4B	68.0B	63.2B	62.1B	65.2B
Short Long Term Debt Total	24.6B	31.4B	26.7B	25.2B	25.0B	26.2B
Other Current Liab	6.5B	7.8B	9.4B	8.1B	11.3B	11.8B
Total Current Liabilities	9.8B	11.4B	11.6B	11.2B	11.3B	11.8B
Total Stockholder Equity	22.7B	18.2B	21.1B	21.2B	22.7B	23.9B
Property Plant And Equipment Net	4.5B	5.0B	5.1B	5.5B	5.3B	5.6B
Net Debt	13.0B	25.4B	21.4B	19.8B	18.9B	19.8B
Retained Earnings	19.4B	14.4B	16.3B	15.7B	16.3B	17.1B
Accounts Payable	713M	844M	705M	905M	550M	518.2M
Cash	11.6B	6.0B	5.3B	5.4B	6.1B	3.8B
Non Current Assets Total	30.1B	52.6B	52.9B	47.9B	45.7B	48.0B
Non Currrent Assets Other	7.7B	6.4B	6.0B	4.0B	5.6B	5.9B
Cash And Short Term Investments	25.8B	7.9B	7.8B	7.6B	8.4B	7.5B
Common Stock Shares Outstanding	1.3B	1.3B	1.3B	1.3B	1.3B	1.5B
Liabilities And Stockholders Equity	61.6B	68.4B	68.0B	63.2B	62.1B	65.2B
Non Current Liabilities Total	29.2B	38.8B	35.3B	30.7B	28.1B	29.5B
Other Current Assets	1.4B	2.0B	2.1B	1.8B	2.4B	1.3B
Other Stockholder Equity	3.2B	3.9B	4.7B	5.5B	(16.3B)	(15.5B)
Total Liab	39.0B	50.2B	46.9B	42.0B	39.4B	41.3B
Total Current Assets	31.5B	15.8B	15.1B	15.2B	16.5B	10.8B
Short Term Debt	2.5B	2.8B	1.5B	2.3B	1.8B	1.9B
Net Receivables	3.6B	4.9B	4.5B	4.8B	4.7B	2.4B
Property Plant And Equipment Gross	4.5B	5.0B	7.0B	7.7B	7.8B	8.2B
Accumulated Other Comprehensive Income	85M	(60M)	83M	2M	28M	37.6M
Short Term Investments	12.7B	1.4B	1.2B	973M	1.2B	1.1B
Inventory	2.1B	3.0B	2.7B	2.8B	3.4B	3.5B
Other Liab	6.5B	9.5B	35.3B	7.3B	8.4B	8.8B
Other Assets	3.1B	4.8B	6.0B	1M	1.2M	1.1M
Long Term Debt	22.1B	28.6B	25.2B	23.0B	23.2B	12.2B
Property Plant Equipment	4.5B	5.0B	5.1B	5.5B	6.3B	6.6B
Net Tangible Assets	4.6B	(23.0B)	(20.7B)	(16.0B)	(14.4B)	(13.7B)
Noncontrolling Interest In Consolidated Entity	125M	19M	(5M)	(31M)	(84M)	(79.8M)
Retained Earnings Total Equity	19.4B	14.4B	16.3B	15.7B	18.0B	12.7B
Long Term Debt Total	22.1B	28.6B	25.2B	23.0B	26.4B	19.7B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

How To Invest In Gilead

Details

Is Gilead Stock a good investment?

Details

What is Gilead Sciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Insider Screener Find insiders across different sectors to evaluate their impact on performance

Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.13)

Dividend Share

Earnings Share

4.5

Revenue Per Share

21.728

Quarterly Revenue Growth

(0.04)

The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gilead Free Cash Flow vs Enterprise Value Analysis

Free Cash Flow vs Enterprise Value

Free Cash Flow vs Enterprise Value Correlation Analysis

Correlation Coefficient

Free Cash Flow

Enterprise Value

Gilead Sciences fundamental ratios Correlations

Gilead Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gilead Sciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Gilead Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Total Liab	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Liabilities	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets
Total Stockholder Equity	+ 0.96	Total Current Liabilities

Other Stockholder Equity	- 0.53	Other Current Liab
Property Plant And Equipment Gross	- 0.52	Other Stockholder Equity
Inventory	- 0.45	Other Stockholder Equity
Non Currrent Assets Other	- 0.44	Accounts Payable
Other Stockholder Equity	- 0.4	Property Plant And Equipment Net
Other Stockholder Equity	- 0.36	Total Stockholder Equity